We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Optical Monitor Continuously Measures Glucose Levels

By HospiMedica International staff writers
Posted on 15 Nov 2012
A new diabetes monitor uses optical spectroscopy to detect blood glucose levels by shining light through the skin and detecting changes in the returning spectrum.

The C8 Medisensors Optical Glucose Monitor System is a novel noninvasive continuous glucose monitor (nCGM) that harnesses the power of light to measure glucose levels. More...
The small, pain-free portable monitor uses Raman spectroscopy, shining a beam of monochromatic light into the skin, with the resulting vibrations of scattered light from glucose molecules measured to give a glucose reading. The colors generated by Raman scattering are very specific to the exact chemical structure of the molecules, with various shapes, sizes, atoms, and types of chemical bonds generating a unique Raman spectra that can be used to noninvasively read and measure glucose.

The device does not require constant recalibration to maintain sensor accuracy. And apart from periodic baseline reference measurements, there is no need for ongoing finger sticks to constantly recalibrate the device; after being removed and put back on, the monitor will resume measuring glucose. For added convenience, the readings can be stored and subsequently sent wirelessly via Bluetooth to the user's smartphone, providing a continuous picture of glucose dynamics throughout the day. The C8 Medisensors optical glucose monitor system is a product of C8 MediSensors (San Jose, CA, USA), and has received the European Community CE marking of approval.

“C8 MediSensors was cofounded by a father trying to help his son living with diabetes, and as a company, we remain dedicated to helping those with the disease,” said Paul Zygielbaum, CEO of C8 MediSensors. “Our team is hugely excited to be working to make nCGM and the Optical Glucose Monitor System available throughout Europe.”

In clinical studies, the C8 MediSensors monitor was found to have accuracy comparable to earlier versions of invasive continuous glucose monitors (CGMs) when those systems were first introduced, but with less pain and less risk of infection. It is contraindicated in pregnancy and for those under 18 years of age, as well as in individuals with very light or very dark skin tones, peripheral vascular disease, or individuals who smoke.

Related Links:

C8 MediSensors



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ultrasound Needle Guidance System
SonoSite L25
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.